Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Harbeck

Showing results (11-20 of 148) with videos related to

Pageof 15
Sort By:
British Journal of Cancer|March 1, 1994
Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-upN Harbeck, M Untch, L Pache, et al.
Seminars in Thrombosis and Hemostasis|June 5, 1999
Thrombophilic state in breast cancerM Schmitt, W Kuhn, N Harbeck, et al.
MMW Fortschritte Der Medizin|July 18, 2003
[Prognostic factors in carcinoma of the breast. Thereupon depends success of the treatment]A Schneeweiss, Ch Thomssen, N Harbeck, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|March 16, 2000
Tumor-associated overexpression of the soluble T1-S receptor in lymph node-negative breast cancerA K Werenskiold, D Prechtel, N Harbeck, et al.
Expert Opinion on Biological Therapy|December 1, 2001
Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumoursB Muehlenweg, S Sperl, V Magdolen, et al.
Hamostaseologie|August 23, 2005
[Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2]K Mengele, N Harbeck, U Reuning, et al.
The International Journal of Biological Markers|April 14, 2000
Neural network analysis of follow-up data in primary breast cancerN Harbeck, R Kates, K Ulm, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|March 10, 2001
Clinical relevance of T1-S, an oncogene-inducible, secreted glycoprotein of the immunoglobulin superfamily, in node-negative breast cancerD Prechtel, N Harbeck, U Berger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2009
Triple-negative breast cancer--current status and future directionsO Gluz, C Liedtke, N Gottschalk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2017
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapyK Blackwell, P Gascon, A Krendyukov, et al.
Pageof 15

Showing results (11-20 of 148) with videos related to

Sort By:
Pageof 15
British Journal of Cancer|March 1, 1994
Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-upN Harbeck, M Untch, L Pache, et al.
Seminars in Thrombosis and Hemostasis|June 5, 1999
Thrombophilic state in breast cancerM Schmitt, W Kuhn, N Harbeck, et al.
MMW Fortschritte Der Medizin|July 18, 2003
[Prognostic factors in carcinoma of the breast. Thereupon depends success of the treatment]A Schneeweiss, Ch Thomssen, N Harbeck, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|March 16, 2000
Tumor-associated overexpression of the soluble T1-S receptor in lymph node-negative breast cancerA K Werenskiold, D Prechtel, N Harbeck, et al.
Expert Opinion on Biological Therapy|December 1, 2001
Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumoursB Muehlenweg, S Sperl, V Magdolen, et al.
Hamostaseologie|August 23, 2005
[Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2]K Mengele, N Harbeck, U Reuning, et al.
The International Journal of Biological Markers|April 14, 2000
Neural network analysis of follow-up data in primary breast cancerN Harbeck, R Kates, K Ulm, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|March 10, 2001
Clinical relevance of T1-S, an oncogene-inducible, secreted glycoprotein of the immunoglobulin superfamily, in node-negative breast cancerD Prechtel, N Harbeck, U Berger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2009
Triple-negative breast cancer--current status and future directionsO Gluz, C Liedtke, N Gottschalk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2017
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapyK Blackwell, P Gascon, A Krendyukov, et al.
Pageof 15